CA2231750C - Hydrolysis-promoting taxane hydrophobic derivatives - Google Patents
Hydrolysis-promoting taxane hydrophobic derivatives Download PDFInfo
- Publication number
- CA2231750C CA2231750C CA002231750A CA2231750A CA2231750C CA 2231750 C CA2231750 C CA 2231750C CA 002231750 A CA002231750 A CA 002231750A CA 2231750 A CA2231750 A CA 2231750A CA 2231750 C CA2231750 C CA 2231750C
- Authority
- CA
- Canada
- Prior art keywords
- taxane
- chx1
- group
- integer
- zero
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940123237 Taxane Drugs 0.000 title claims abstract description 99
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 85
- 230000002209 hydrophobic effect Effects 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 241001465754 Metazoa Species 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 101001003232 Mus musculus Immediate early response gene 2 protein Proteins 0.000 claims abstract 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 150000002632 lipids Chemical class 0.000 claims description 48
- 239000002502 liposome Substances 0.000 claims description 38
- 230000001093 anti-cancer Effects 0.000 claims description 16
- 239000012867 bioactive agent Substances 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 238000006467 substitution reaction Methods 0.000 abstract description 6
- 230000007062 hydrolysis Effects 0.000 abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 229930195733 hydrocarbon Natural products 0.000 abstract description 3
- 150000002430 hydrocarbons Chemical class 0.000 abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 description 45
- 229930012538 Paclitaxel Natural products 0.000 description 44
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 44
- 125000002252 acyl group Chemical group 0.000 description 35
- 150000004579 taxol derivatives Chemical class 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 231100001231 less toxic Toxicity 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 229930190007 Baccatin Natural products 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000145525 Spinach latent virus Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000002456 taxol group Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SYDMVWLQJZBPIU-VHLOTGQHSA-N 19-hydroxybaccatin iii Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(CO)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 SYDMVWLQJZBPIU-VHLOTGQHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229930014667 baccatin III Natural products 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- ADDGUHVEJPNWQZ-FIKJQGJASA-N 10-Deacetylcephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C\C)/C)c1ccccc1 ADDGUHVEJPNWQZ-FIKJQGJASA-N 0.000 description 1
- TYLVGQKNNUHXIP-MHHARFCSSA-N 10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 TYLVGQKNNUHXIP-MHHARFCSSA-N 0.000 description 1
- ADDGUHVEJPNWQZ-GJKIWTKTSA-N 10-deacetyltaxol b Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 ADDGUHVEJPNWQZ-GJKIWTKTSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 1
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 1
- YWLXLRUDGLRYDR-LUPIKGFISA-N 7-epi-10-deacetylbaccatin iii Chemical group O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-LUPIKGFISA-N 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101150003532 CSH gene Proteins 0.000 description 1
- 102220603102 Cadherin-related family member 1_C53H_mutation Human genes 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101100532699 Drosophila melanogaster scyl gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100112336 Homo sapiens CASP5 gene Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical compound OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 241000288940 Tarsius Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 101150048033 cbh gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Abstract
Provided herein is a taxane having the formula: (see formula I) wherein: A1 is H or a group having the formula Z-C(O)NHCH(C6H5)CH(OR)-C(O)-, A2 is H or CH3C(O)- and A3 is H or OH; Z is C6H5-, C6H5CH2-O-, C(CH3)3-O- or CH(CH3)=C(CH3)-; each of R and R1 is H or a group having the formula Y1Y2, provided that at least one of R and R1 is not H; Y1 is -C(O)CHX1(CH2)n1(CH=CH)n2(CH2)n3(CH=CH)n4(CH2)n5 (CH=CH)n6(CH2)n7(CH=CH)n8(CH2)n9-: the sum of n1 + 2n2 + n3 + 2n4 + n5 +2n6 + n7 + 2n8 + n9 is an integer of from 1 to 21, each of n2, n4, n6 and n8 is independently zero or 1, n1 is zero or an integer of from 1 to 21, n3 is zero or an integer of from 1 to 18, n5 is zero or an integer of from 1 to 15, n7 is zero or an integer of from 1 to 12, n9 is zero or an integer of from 1 to 9 and each of n1 to n9 can be the same or different at each occurrence; X1 is an hydrolysis-promoting group which exhibits an electronegativity greater than hydrogen; and Y2 is -CH3, -CO2H or -CH2OH which has a hydrocarbon attached at the 2' and/or 7 positions, the hydrocarbons alpha position being occupied by a "hydrolysis-promoting group" ("HPG"). Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and uses of those compositions for treating animals, including those afflicted with cancers, and also the use of the compositions for the manufacture of a medicament for the treatment of cancer.
Description
HYDROLYSIS-PROMOTING TA~AN Y M 1 1VAT1 Field of the Inw~ntion This invention provides compounds which are a taxane to which an scyl chain has been attached: the acyl chain has been derrvatized by the ariachment thereto of a hydrolysis promoting group. Also provided herein are compositions comprising such campvunds, including lipid carrier-containing pharmaceutical compositions, and methods of administering such compositions to animals, such as humans afflicted with cancers.
~.c~caround of the Invention Taxanes can be isolated from natural sources, and can also be prepared synthetically from naturally occurring precursors. Paclitaxel (TAXOL'~, Bristol-Myers Squibb), far example, can be prepared from baccatin by attachment of protecting groups to the hydroxyl groups of baccatin that are to became the hydroxyl groups of paclitaxel. converting the precursor 1 S baccatin to paclitaxel, and then removing the protecting groups from the hydroxyl groups to obtain paclitaxel (see, e.g., W093I10076, int. pub. date 05127!'93; K. V, Rao, U.S. Patent No.
5.200.534: R.A. Hofton, U.S. Patent Na. 5,015, 744; WC~ 9~/f~6070; V.J. Stella and A.E.
Mathew, U.S. Patent No. 4,960,790: K.C. Nicotau. Nature ,~4 (1993), pp. a64-466; Nicalau, K.
C. et aL Nature ~7 (1994) pp.630-634: Hoflon, R. A., et e!. J. Am. Chem. 8oc.
,u,ø (1994) pp.
1597-1600: W093116059, int. pub. date Ct8~19/93; EP 528.729, published 02!24!93; EP
522.958, published 01/13193; W091/13053, int. pub. date 09!05191; EP 414,610, int. pub. date 02127/91 ).
Taxanes can be used effectively to treat a variety of cancers. Paclitaxel, far example, has been found to have activity against ovarian and breast cancers, as well as against malignant melanoma, colon cancer, leukemias and lung cancer ($ee, e.g., Borman, Chemical 8 Engineering News. September 2. 1991, pp,. 1 i-18; The Phamtacological Basis of Therapeutics (Goodman Gitman et al., eds.), Pergamon Press. New York (1990), p. 1239;
Suffness, Antitumor Alkaloids, in: '?he Alkalcsids, Vol. X5(V," Academic Press, inc. (1985), Chapter 1, pp. 6-18; Rizxo et al., J. Pharm. 1~ Biomed. Anal. x(2):159-164 (1990); and Biotechnology x:933-938 (October, 1991 ). f'aclitaxel acts against cancer ceifs by binding to tubufin in the cells nucier, thereby blocking the disassembly of micratubules and consequently, inhibiting cell division (Schitf et al., Nature ~?:685 (1979).
However, formulation of taxanes in therapeutically useful carriers. so as to enable the taxanes to be administered to animals, is made difficult by the nature of the taxane molecules.
which can be poorly soluble pr both aqueous and lipid carriers. Paclitaxel, far example. is currently supplied as an emulsion in a poiyoxyeihylated derivative of costar oil and ethanol CremophorEL~ because of its Pack of significant aqueous or lipid solubility.
However, as the cremophor carrier can itself be toxic to animals, administration of the cremophor-based paclitaxel formulation generally entails premedication with other drugs, as well as a slow infusion of a large volume of the formulation, thus necessitating over night hospital stays and their attendant costs.
Compositions provided herein provide taxanes in the form of compounds which are taxanes to which an acyl chain has been attached. The acyl chain enhances the taxane's lipid solubility, such that the taxane can be stably associated with a lipid-based carrier, e.g., a liposome, for an extended period of time. The acyl chain itself has been derivatized by the attachment thereto of a hydrolysis-promoting group, which is a chemical moiety that promotes hydrolysis of the derivatized acyl chain from the parent taxane, once the taxane has been disassociated from the lipid-based carrier, so as to give the parent taxane in a therapeutically useful form.
The compounds provided herein can be administered to animals as such, or may be formulated together with a lipid-based carrier prior to administration. Such formulations enhance delivery of the taxane to its intended site of action in an animal.
~.c~caround of the Invention Taxanes can be isolated from natural sources, and can also be prepared synthetically from naturally occurring precursors. Paclitaxel (TAXOL'~, Bristol-Myers Squibb), far example, can be prepared from baccatin by attachment of protecting groups to the hydroxyl groups of baccatin that are to became the hydroxyl groups of paclitaxel. converting the precursor 1 S baccatin to paclitaxel, and then removing the protecting groups from the hydroxyl groups to obtain paclitaxel (see, e.g., W093I10076, int. pub. date 05127!'93; K. V, Rao, U.S. Patent No.
5.200.534: R.A. Hofton, U.S. Patent Na. 5,015, 744; WC~ 9~/f~6070; V.J. Stella and A.E.
Mathew, U.S. Patent No. 4,960,790: K.C. Nicotau. Nature ,~4 (1993), pp. a64-466; Nicalau, K.
C. et aL Nature ~7 (1994) pp.630-634: Hoflon, R. A., et e!. J. Am. Chem. 8oc.
,u,ø (1994) pp.
1597-1600: W093116059, int. pub. date Ct8~19/93; EP 528.729, published 02!24!93; EP
522.958, published 01/13193; W091/13053, int. pub. date 09!05191; EP 414,610, int. pub. date 02127/91 ).
Taxanes can be used effectively to treat a variety of cancers. Paclitaxel, far example, has been found to have activity against ovarian and breast cancers, as well as against malignant melanoma, colon cancer, leukemias and lung cancer ($ee, e.g., Borman, Chemical 8 Engineering News. September 2. 1991, pp,. 1 i-18; The Phamtacological Basis of Therapeutics (Goodman Gitman et al., eds.), Pergamon Press. New York (1990), p. 1239;
Suffness, Antitumor Alkaloids, in: '?he Alkalcsids, Vol. X5(V," Academic Press, inc. (1985), Chapter 1, pp. 6-18; Rizxo et al., J. Pharm. 1~ Biomed. Anal. x(2):159-164 (1990); and Biotechnology x:933-938 (October, 1991 ). f'aclitaxel acts against cancer ceifs by binding to tubufin in the cells nucier, thereby blocking the disassembly of micratubules and consequently, inhibiting cell division (Schitf et al., Nature ~?:685 (1979).
However, formulation of taxanes in therapeutically useful carriers. so as to enable the taxanes to be administered to animals, is made difficult by the nature of the taxane molecules.
which can be poorly soluble pr both aqueous and lipid carriers. Paclitaxel, far example. is currently supplied as an emulsion in a poiyoxyeihylated derivative of costar oil and ethanol CremophorEL~ because of its Pack of significant aqueous or lipid solubility.
However, as the cremophor carrier can itself be toxic to animals, administration of the cremophor-based paclitaxel formulation generally entails premedication with other drugs, as well as a slow infusion of a large volume of the formulation, thus necessitating over night hospital stays and their attendant costs.
Compositions provided herein provide taxanes in the form of compounds which are taxanes to which an acyl chain has been attached. The acyl chain enhances the taxane's lipid solubility, such that the taxane can be stably associated with a lipid-based carrier, e.g., a liposome, for an extended period of time. The acyl chain itself has been derivatized by the attachment thereto of a hydrolysis-promoting group, which is a chemical moiety that promotes hydrolysis of the derivatized acyl chain from the parent taxane, once the taxane has been disassociated from the lipid-based carrier, so as to give the parent taxane in a therapeutically useful form.
The compounds provided herein can be administered to animals as such, or may be formulated together with a lipid-based carrier prior to administration. Such formulations enhance delivery of the taxane to its intended site of action in an animal.
SUMMARY OF THE INVENTION
This invention provides a taxane having the formula:
)R1 ADO' O
wherein: A' is H or a group having the formula Z-C(O)NHCH(CeHs)CH(OR)C(O)-; Z
is Calls-, CaH5CH2-O-, C(CH3)3-O- or CH(CH3)=C(CH3)-; AZ is H or CH3C(O)-; and A3 is H or OH. Each of R and R' is H or a group having the formula Y'YZ, provided that at least one of R and R' is not H.
Y' is a group having the formula -C(O)CHX'(CH=)"~(CH=CH)"z(CHZ)"s(CH=CH)",(CH2)"s(CH=CH)"e(CHZ)"~(CH=CH)",(CHZ)"9 -.
The sum of n1 + 2n2 + n3 + 2n4 + n5 +2n6 +n7 +2n8 + n9 is an integer of from 1 to 21, with each of n2, n4, n6 and n8 being independently zero or 1. nt is equal to zero or an integer of from 1 to 21, n3 is equal to zero or an integer of from t to 18, n5 is equal to zero or an integer of from 1 to 15, n7 is equal to zero or an integer of from 1 to 12, n9 is equal to zero or an integer of tram 1 to 9, and each of n1 to n9 can be the same or different at each occurrence.
Y2 is -CH3, -COZH or -CHZOH.
X' is a hydrolysis promoting group ("HPG") including, but not limited to: F, CI, Br, I, the group -OCeH,XZ or the group -C(O)X2, wherein XZ is F. CI, Br, I, NH3', NOZ or CN. Most preferably, X' is F, CI, Br or' I. Preferably, A1 is the group Z-C(O)NHCH(C6H5)CH(OR)C(O)-: Z
is preferably C6H5 and A' is more preferably the group C6HSC(O)NHCH(CBHS)CH(OR)C(O)-.
Most preferably, A' is C6H5~;,(O)NHCH(CgHs)CH(OR)C(O)-, AZ is CH3C(O)- and A3 is H, that is, ~O
the taxane is a paclitaxel. When R' is a hydrogen, R is then -Y'Yz, and when R
is a hydrogen, R' is -Y'Y2. The group -Y'Y2 preferably has the formula -Y'CH3, more preferably, the formula -C(O)CHX'(CH2)"ICH3. Most preferably, n1 is then 3, 5, 9, 11, 13 or 15.
Also provided herein are compositions comprising the taxane of this invention;
such compositions can also comprise a pharmaceutically acceptable medium. The compositions preferably also comprises a lipid-based carrier, e.g., a fatty acid, phospholipid, lipoprotein, ' micelle, lipid complex or liposome, with which the taxane is associated so as to deliver the taxane to a site in the body where it can be therapeutically effective.
Further provided herein is a method of administering a taxane to an animal, which comprises administering a taxane-containing composition of this invention to the animal. The animal can be afflicted with a cancer, e.g., a brain, stomach, lung, colon, prostate, breast or ovarian cancer, or a leukemia, lymphoma, carcinoma or sarcoma. Cancer treatment by this method involves administering an anticancer effective amount of a taxane to the affected animal. Typically, this anticancer effective amount of the taxane is from about 0.1 mg per kg of body weight of the animal to about 1000 mg per kg. For such anticancer treatment, the composition administered preferably contains a lipid carrier. Preferred anticancer taxanes are paclitaxels, i.e., taxanes wherein A1 is C6H5C(O)NHCH(C6H5)CH(OR)C(O)-, A2 is CH3C(O)-and A3 is H. More preferably, R or R' is -C(O)CHX'(CH2)",CH3, and most preferably, ni is then 3, 5, 9, 11, 13 or 15. Furthermore, an additional bioactive agent can be administered to an animal as part of administration of a taxane to the animal.
BRIEF DESCRIhTION OF THE DRAWING
FIGURE 1. Effect of Paclitaxel- and 2'-(2-Bromo) Hydrophobic Paclitaxel Derivative ("HTD")-Containing Liposomes on the Survival of OVCAR3 Tumor-Bearing SCID
Mice.
Filled diamonds: paclitaxel fiposomes; filled squares: 2-bromo-C6 HTD
(paclitaxel substituted with a 6-carbon acyl chain attached to paclitaxel's 2' hydroxyl group, the acyl chain having a bromine atom attached to its alpha carbon); filled triangles: 2-bromo-C8 HTD; open diamonds: 2-bromo-C12 HTD; open triangles: 2-bromo-C14 HTD; open circles: 2-bromo-C16 HTD; and, '. "empty" liposomes (liposomes not containing paclitaxel or a substituted paclitaxel derivative).
This invention provides a taxane having the formula:
)R1 ADO' O
wherein: A' is H or a group having the formula Z-C(O)NHCH(CeHs)CH(OR)C(O)-; Z
is Calls-, CaH5CH2-O-, C(CH3)3-O- or CH(CH3)=C(CH3)-; AZ is H or CH3C(O)-; and A3 is H or OH. Each of R and R' is H or a group having the formula Y'YZ, provided that at least one of R and R' is not H.
Y' is a group having the formula -C(O)CHX'(CH=)"~(CH=CH)"z(CHZ)"s(CH=CH)",(CH2)"s(CH=CH)"e(CHZ)"~(CH=CH)",(CHZ)"9 -.
The sum of n1 + 2n2 + n3 + 2n4 + n5 +2n6 +n7 +2n8 + n9 is an integer of from 1 to 21, with each of n2, n4, n6 and n8 being independently zero or 1. nt is equal to zero or an integer of from 1 to 21, n3 is equal to zero or an integer of from t to 18, n5 is equal to zero or an integer of from 1 to 15, n7 is equal to zero or an integer of from 1 to 12, n9 is equal to zero or an integer of tram 1 to 9, and each of n1 to n9 can be the same or different at each occurrence.
Y2 is -CH3, -COZH or -CHZOH.
X' is a hydrolysis promoting group ("HPG") including, but not limited to: F, CI, Br, I, the group -OCeH,XZ or the group -C(O)X2, wherein XZ is F. CI, Br, I, NH3', NOZ or CN. Most preferably, X' is F, CI, Br or' I. Preferably, A1 is the group Z-C(O)NHCH(C6H5)CH(OR)C(O)-: Z
is preferably C6H5 and A' is more preferably the group C6HSC(O)NHCH(CBHS)CH(OR)C(O)-.
Most preferably, A' is C6H5~;,(O)NHCH(CgHs)CH(OR)C(O)-, AZ is CH3C(O)- and A3 is H, that is, ~O
the taxane is a paclitaxel. When R' is a hydrogen, R is then -Y'Yz, and when R
is a hydrogen, R' is -Y'Y2. The group -Y'Y2 preferably has the formula -Y'CH3, more preferably, the formula -C(O)CHX'(CH2)"ICH3. Most preferably, n1 is then 3, 5, 9, 11, 13 or 15.
Also provided herein are compositions comprising the taxane of this invention;
such compositions can also comprise a pharmaceutically acceptable medium. The compositions preferably also comprises a lipid-based carrier, e.g., a fatty acid, phospholipid, lipoprotein, ' micelle, lipid complex or liposome, with which the taxane is associated so as to deliver the taxane to a site in the body where it can be therapeutically effective.
Further provided herein is a method of administering a taxane to an animal, which comprises administering a taxane-containing composition of this invention to the animal. The animal can be afflicted with a cancer, e.g., a brain, stomach, lung, colon, prostate, breast or ovarian cancer, or a leukemia, lymphoma, carcinoma or sarcoma. Cancer treatment by this method involves administering an anticancer effective amount of a taxane to the affected animal. Typically, this anticancer effective amount of the taxane is from about 0.1 mg per kg of body weight of the animal to about 1000 mg per kg. For such anticancer treatment, the composition administered preferably contains a lipid carrier. Preferred anticancer taxanes are paclitaxels, i.e., taxanes wherein A1 is C6H5C(O)NHCH(C6H5)CH(OR)C(O)-, A2 is CH3C(O)-and A3 is H. More preferably, R or R' is -C(O)CHX'(CH2)",CH3, and most preferably, ni is then 3, 5, 9, 11, 13 or 15. Furthermore, an additional bioactive agent can be administered to an animal as part of administration of a taxane to the animal.
BRIEF DESCRIhTION OF THE DRAWING
FIGURE 1. Effect of Paclitaxel- and 2'-(2-Bromo) Hydrophobic Paclitaxel Derivative ("HTD")-Containing Liposomes on the Survival of OVCAR3 Tumor-Bearing SCID
Mice.
Filled diamonds: paclitaxel fiposomes; filled squares: 2-bromo-C6 HTD
(paclitaxel substituted with a 6-carbon acyl chain attached to paclitaxel's 2' hydroxyl group, the acyl chain having a bromine atom attached to its alpha carbon); filled triangles: 2-bromo-C8 HTD; open diamonds: 2-bromo-C12 HTD; open triangles: 2-bromo-C14 HTD; open circles: 2-bromo-C16 HTD; and, '. "empty" liposomes (liposomes not containing paclitaxel or a substituted paclitaxel derivative).
D~'TAILED DESCRIPTION OF THE INVENTION
This invention provides a taxane having the formula:
A~ O' 5 A~ is H or a group having the fom~uia Z~C(O)NHCH(C,Hs)CH(OR)C(O)-, A~ is H
or CHsC(O)-, and A~ is H or OH. Z is CdHs, CdHsCH2-O-. C(CHs)r0- or CH(CH')=C(CH~-~ Most preferably.
A~ is CaHsC(O)NHCH(CsHs)CH(OR)C(O}-, A~ is CH'C(O)- and A~ ~ H. Accordingly, the .
taxane most preferred herein is a paditaxel ([Cort>pound f); TAXOL~ (C"Hs,NO), l3ristd-Myers Squibb) derivative.
Howe~t, '"' 111)~based derivatives, which differ from pad'rtaxel by having a tsrt-brrtoxy carbonyl group at the C-12 position, instead of a bertzoyl gn~up, and a hydroxyl group, instead of an acetyloxy group, at C-10 are also provided heroin. Aocadingly, fnr taxotereT", Al is C(CHI)~OC(O)NHCH(C,HS)CH(OR)G(O)-, A2 is H, and As is H.
Further taxanes useful in accordance with the practice of this invention irxlude, without limitation: Cephalomannine (111); 19-hydroxybaccatin III [IVJ, Baa~tin V (Vj.
10-deacetyl cephalomannine [VI], 10-deacetyl paclitaxel [YIIj, 7~lpi-10-deacetyl paditaxel (Vltlj, 7-Epi-10-deacetyl cephalomannine [17C], and 10-deacetyl baccatin Ill (X], as described in the following 20 table.
_5.
Compound 1 p PactitaxelC6HSC(O)NHCN(CBHs) CH M
C(O)-(I) CH(OR)C(O)- ~
TaxotereT"'C(CH3)3OC(O)NHCH H H
(11) (C6H~)CH(OR)C(O)-Cephalo- (CH3)CH=C(CH9)C(O)NHCHCH3C(O)- H
i mann (CgH$)CH(OR)C(O)-ne (111) 19-hydroxyH
CH3C(O). OH
baccatin III
(IV) Baccatin H CH H
III C(O)-10-Deacetyl(CH~)CH=C(CH3)C(O) H H
cephalo NHCH(C
H
)CH(OR) C(O)-mannine 6 (VI) ceryi C'HsC(O)NHCH(C M H
e H
) taxol 6 "' 6 CH(OR)C(O).
(VII) (7a-OH) 7-Epi-10-C6HSC(O)NHCH(C H H
H
) deaceNi 6 ~
~,H(OR)C(O)-ta~cOIT"'(7~-OH) (VIII) 7-Epi-10- (CH3)CH=C(CH~)C(O) H H
deacetyi NHCH(C6Hs)CH(OR)C(O)-cephalo mannme(7~-OH) (IX) 10-Deacetyl H H H
baccatin III
(X) Each of R and R' is H or a graup having the formula -Y'Y2, provided that at least one of R and R' is not H. Y' is the group -C(O)CHX'(CH2)"~(CH=CH)n2(CH2)"s(CH=CH)nalCl"(a)"x(CH=CH)"s(CHz)"~(CH=CH)"e (CHZ)n9~-~ The sum of n1 +2n2 + n~ + 2n4 + n~ + 2n6 + n~ + 2n8 + ng+ is an integer of from 1 to 21, -~,-wherein each of n2, n4, n6 and n8 is independently zero or 1. n1 is equal to zero or an integer of from 1 to 21, n3 is equal to zero or an integer of from 1 to 18, n5 is equal to zero or an integer of from 1 to 15, n7 is equal to zero or an integer of from 1 to 12, and n9 is equal to zero or an integer of from 1 to 9. Each of ni to n9 can be the same or different at each occurrence.
Preferably, Y' is saturated, that is, there are no double bonds between adjacent carbon atoms.
Accordingly, n2, n4, n6 and n8 are each preferably zero, n3, n5, n7 and n9 are each also zero, and Y~ is preferably -C(O)CHX'(CH2)~~-. Alternatively, Y' can be unsaturated, that is, it can have one or more double bonds and one or more CH=CH units; accordingly, at least one of n2, n4, n6 and n8 is then 1. For example, when the unsaturated acyl chain has one double bond: n2 is 1, n4, n6 and n8 each being zero; Y~ is then -C(O)CHX'(CHZ)~~CH=CH(CH2)~ ; ni is zero or an integer from 1 to 18; n3 is also zero or an integer from 1 to 18, at feast one of ni or n3 is not zero, and the sum of n1 plus n3 is equal to an integer of from 1 to 19.
Y2 is preferably -CH3, the acyl chain thus being derived from a monocarboxylic acid, but can also be -COZH, the acyl chain being derived from an omega dicarboxylic acid, or -CHZOH, the acyl chain then being derived from an omega hydroxy acid.
Accordingly, the group Y'Y2 preferably has the formula -C(O)CHX'(CHZ)"~CH3, wherein n1 is most preferably equal to 3, 5, 9, 11 or 13, whether the group be located at R, R' or both R
and R'.
"Attachment" of the group -Y'Y2 to a taxane means forming a chemical connection between the group and the taxane by any means generally accepted in the art for forming such connections. Attachment is to one or more reactive groups, typically hydroxy groups, on the taxane. Attachment of any acyl chain to a taxane can stabilize the taxane-lipid carrier association, such that the taxane an carrier remain together, for example, in the plasma of animals for a longer period of time than does the corresponding acyl chain-free taxane.
Increased stability of association enhances the amount of the taxane reaching its intended site of therapeutic action in vivo.
Paclitaxel, for example, has two hydroxyl groups to which acyl chains can be attached;
these are located at the 2' and 7 positions, with their relative order of reactivity generally believed to be (from most reactive to least reactive) 2'>7. Hydrocarbons can be attached to the primary reactive group of a taxane, e.g., the 2' OH group of paclitaxel, utilizing stoichiometric amounts of the an active form of the acid, e.g., chlorides or anhydrides. The hydroxyl group at the 7 position of paclitaxel can be modified by attaching an acyl chain to both the 2' and 7 OH groups, and then selectively removing the 2' acyl chain so that the acyl chain at the 7 position remains attached to paclitaxel. Selective removal of the 2' acyl chain can be accomplished using stoichiometric amounts of a mild base, e.g., sodium bicarbonate.
_7_ Additionally, the 7 OH group of paclitaxel can be modfied by "protecting" the 2' OH gn~p before covalently linking paclitaxel with the acyl chain. The 2' OH group can also be protected with groups such as, for example, triphenyl methyl, methoxytriphenyl methyl, fifiuoroacetyl and TrOC (trichloromethoxy chlorofortnatej groups, using processes generally known to ordinarily skilled artisans. The protected paclitaxel is then reacted with an active form of the acyl chain, e.g., anhydrides or chlorides, in anhydrous organic sohrent, and bases such as DMAP and pyridine. The protecting group can be removed from the 2' position by well known and readily practiced means, under mildly acidic or basic conditions: TtOC groups, for example, can be removed by zinc reduction reactions.
1O' Reactions are typically perforated in the presence of a base, such as pyridine, dimethylaminopyridine ("DMAP"y. triethytamine, or others, and in common polar, aprotic organic solvents such as dimethyl fotmamide: dimethyl sulfoxide and the bke.
The progress of the reaction can be monitored by a number of well known chromatographic means, for example, thin layer chromatography using a 3% methanol-in-chloroform solvent system. The compound's identity can be confimted by spectroscopic proceduros, such es NMR
spectroscopy.
For example, the following reaction scheme, and the infomtation described bek~nr, can be used to prepare 2'-(~-2-8'omoacyl paclitaxels:
Leo O OH ADO
r r Fatty acitltDCC O O
off DMAP. CHZCIy Ph J
=~ IS trtin, r.t. ~ OR' =AeD
PhtOb O
R'= ~ : R"sH
r 1.3-Dieyebtiexylcarbodiitude R. a ~ ; R-. H
O r R.a ; R"sH
s.Dimethylaminopy~asne r NICFt;)z R~a rwW.: R"all Or R~= ; R"all However: specific reaction and purificatwn conditions are generally expedsd to vary according to a number of factors, including without limitation, the raw materials and reactants used, that are well within the purview of ordinarily skilled artisans to determine and control given the teachings of this invention.
Acyl chains substituted with a hydrolysis-promoting group on the alpha carbon can be purchased from commercially available sources, or synthesized according to any of the means . generally accepted in the art for substitution of a hydrogen atom on the alpha carbon of a fatty acid.
"Hydrolysis-promoting-groups" ("HPGs") are substitutions at an acyl chain's alpha carbon (Ca) that promote hydrolysis of the bonds between a parent taxanes its attached acyl chain. HPGs are electronegative relative to hydrogen, meaning that they draw electrons to themselves more than a hydrogen atom would if it occupied the same position in the same molecule. Accordingly, substitution of a hydrolysis-promoting group for a hydrogen atom on the alpha carbon results in a redistribution of an acyl chain's electron density, and thereby causes an inductive effect in the acyl chain. Substitution of aromatic moiety-containing HPGs for alpha carbon-attached hydrogens can also cause resonance effects, these too involving electron density redistribution in the substituted acyl chain. HPG-induced induction and resonance effects stabilize an acid's corresponding base form, but not the acid itself, and thereby causes the acid to be a stronger acid than it would be if there was a CH2 group in the acyl chain instead of the HPG. HPG-substituted acyi chains thus generally have lower pK,'s than their corresponding native forms, that is, the form in which a CHz group is present at the alpha position instead of an HPG-substituted group, and hence, HPG-substituted acyl chains' are more readily hydrolyzable from their parent taxanes than are nonsubstituted chains.
Accordingly, the hydrolysis-promoting group X' can be any atom or group of atoms: (1) having an electronegativity greater than hydrogen; and, (2) that can be attached at the alpha position of an acyl chain. X' can, for example, be F, CI, Br, I, NH3*, the group -OCsH4X2 or the group C(O)X2; XZ is, for example, F, CI, Br, I, NH3*, NOZ or CN. Preferably, X' is F, CI, Br or 1.
Also provided herein is a composition comprising a taxane of this invention.
Compositions intended for therapeutic use of the taxane preferably also comprise a pharmaceutically acceptable medium, which is a medium generally intended for use in connection with the administration of active ingredients, such as therapeutic or diagnostic agents, to animals. These include, without limitation: solids, such as pills, capsules and tablets; gels; excipients; and aqueous or nonaqueous solutions.
Pharmaceutically acceptable media are generally formulated according to a number of factors well within the purview of the orciinarily skilled artisan to determine and account for, including without limitation: the particular - active ingredient used, its concentration, stability and intended bioavailability; the disease, disorder or condition being treated with the composition; the subject, its age, size and general cond'ttion: and the composition's intended route of administration, e.g..
nasal, oral, ophthaunic, topical, transdermal, vaginal. subcutaneous, intramammary, intraperrtoneal, intravenous, or intramuscular (see, for example. J. G. Naim, in: R~,minrrton's Pharmaceutical Science (A.
Gennaro, ed.), Mack Publishing tyo., Easton, PA, (1985), pp. 1492-1517).
Typical pharmaceutically acceptable media used in parenterai drug administration include, for example, DSW, an aqueous solution containing S°/a weight by volume of dextrose, and physiological saline.
Texans-containing compos'ttion6 provided herebn prefet~ comprwse a . lipid carrier with which the taxane is associated, "Lipid carriers" are hydrophobic or annphipathic molecules suitable for administration to animals, and include, without limitation: fatty acids, phosphalipids, micelles, lipoproteins, lipid complexes, i.e., nonliposomal, lipid-based structures which may, but are not required to contain one or more nanlipid components, and liposomes. Preferably, the lipid carrier is a tiposome.
"Liposomes" comprise one or more bilayers of lipid molecules, each biiayer encompassing an aqueous compartment. Unitamellar liposomes have a single lipid bilayer, and multilamellar liposomes have more than one bilayer. The amphipathic lipid molecules which make up lipid bilayers comprise a paler (hydrophilic) headgroup and one or two aryl chains. The polar groups can be phosphate-> sulfate- or nitrogen-based groups, but are preferably phosphate groups, such as phosphorylcholine, phosphoryiethanolamine, phosphorylserine, phosphorylglycerol or phosphorylinositol groups. The acyl chains generally comprise from 12 to 24 carbon atoms, and can be saturated (e.g., lauric, mytistic, palmftic, or stearic acid), or unsaturated (e.g., oleic, linaleic, linolenic, or arachidonic acid). Liposomal lipid can also include sterols, such as cholesterol, and other IipHds.
Liposomes can be made by a variety of methods, including: f3angham's methods for making multilamellar liposomes (MLVs) invohring drying of a lipid/organic solvent solut'ron and then rehydrating the dried lipids with an aqueous solution (see Bangham et al., 1965); Lenk's, method for making MLVs wrth substantially equal interiamellar solute distribution (SPLVs) involving forming a. biphasic mixture tat an aqueous phase end a lipid-containing organic phase, and then emulsifying the lipid in the aqueous phase while evaporating the organic (see U.S. Patent Nos. 4,522,803, 5,030,453, and 5.~69,fi37); Fountain's (U.S.
Patent No.
x.588,578) method of making SPLVs using a monophasic solvent system; Cullis' (U.S. Patent No. 5,008,050) method of making SPLVs using repeated cycles of treezing and thawing;
preparation of REVs through tormation of a water-in-oil emulsion, from which the organic phase is evaporated to give a gel, the gel then being agitated to give oligolamellar liposames (see Papahadjopoulos et al., U.S. Patent No. 4,235.871 ); extrusion of MLVs to make unilamellar liposomes (see, e.g., Cullis et al., U,S. Patent No. 4,975,282);
as well as sonication or homogenization of larger liposomes, or ether or ethanol injection processes (see, for example, R. Dearrter and P. Uster, "Liposome Preparation:
Methods and Mechanisms," in Linoso n ~ (M. C7stra, ed.), Marcel Dekker, Inc., New 'York (1983), pp.27-52).
"Association" as used herein generaltyr means association between the aryl chain attached to the taxane and the hydrophobic portion of the lipid tamer. Without intending to be limtted by theory, it is believed that such association is by way of a number of influences, such as Van der Weal's forces, generally known to operate between hydrophobic malecules in an aqueous environment. Means of determining the stability of such associations, for example.
by determining the percentage of taxane recoverable with phosphorous when the lipid tarsier comprises a phospholipid are readily practiced by ordinarily skilled artisans given the teachings of this invention.
Lipid tamers associated with the taxane of this invention can comprise an additional bioactive agent, that is, a bioactive agent in addft'ron to the taxane. Lipid carrierlbioact'rve agent formulations can enhance the therapeutic index of the bioactive agent, for example by buffering the agent's toxicity and by reducing the rate at which the agent is cleared from the ciroulation of animals, thereby meaning that less of the agent need be administered to achieve the desired therapeutic effect. "Bioactive agents" are compounds or compositions of matter having biological activity on animal cells in vtro or when administered to an animal; bioactive agents can have therapeutic andlor diagnostic activity. Such agents include, but are not limited to, antimiccobial, anti-inflammatory and anticancer agents as well as radioactive isotopes, enzymes and dyes. Additional bioactive agents also include bioackive lipids, such as certain ceramides and ether lipids, which themselves have therapeutically beneficial properties. Preferably, the addttional bioactrve agent is an anticancer agent.
Lipid carriers can also comprise one or more "headgroup-mortified lipids."
These comprise polar groups derivatized by attachment thereto of a moiety which can inhib'tt the binding of serum proteins to headgroup-modified lipid-containing lipid carriers. This afters the pharmacokinetic behavior of the carriers such that they remain in circulation longer (see, e.g., Blume et al., Biochim. Biophys. Acta. 114 :180 (1993): Gabizon et al., Pharm.
Res. x,0_(5):703 (1993): Park et at. Biochim. Biophys Acta. ~Q~:257 (1992); Woodie et al., U.S.
Patent No.
5.013.556; Allen et al., U.S. Patent Nos. 4,837,028 and 4,920,016).
_f1_ Headgroup-modified lipids are typically phosphatidylethanoiamines (PE's), for example dipalmitoyl phosphatidylethanoiamine (°DPPE°), palmitoyloteoyl phosphatidylethanoiamine ("POPE") and dioleoyl phosphatidylethanolamine ("DOPE"), amongst others. Such lipids have headgroups generally derivatized with organic dicarboxyiic acids, such as succinic or gfutaric ,.
acid ("GA"), or their corresponding anhydrides.
The amount of the headgroup-modified lipid incorporated into the lipid carrier generally depends upon a number of factors well known to the ordinarily skilled artisan, or within his purview to determine without undue experimentation. These include, but are not limited to: the type of lipid and the type of headgroup modification; the type and size of the carrier; and the intended therapeutic use of the formulation. Typically, from about 5 mole percent to about 20 mote percent of the lipid in a headgroup-modified lipid-containing lipid carrier is headgroup-modified lipid.
Further provided herein is a method of administering a taxane to an animal, which comprises administering the composition of this invention to the animal, preferably a mammal such as a human. Administration is by any other means generally accepted for administration of therapeutic agents to animals, but is preferably intravenous or intraperitoneal. Animals afflicted with cancers can be treated by therapeutic administration of taxane-containing compositions, wherein the compositions comprise an anticancer effective amount of a taxane.
Generally, those cancers treatable by this method are those which are, or may be, treated with the corresponding free taxane, i.e., a taxane not having an attached acyl chain.
These include, without limitation: brain, breast, colon, lung, ovarian, prostate, pancreatic and stomach cancers; as well as, leukemias, lymphomas, sarcomas and carcinomas.
Preferably, the treated cancer is a breast or ovarian cancer. The cancer treated can be a cancer that is resistant to standard therapeutic regimens, i.e., a drug-resistant cancer.
A taxane's anticancer activity can be determined by examining the taxane's ability to inhibit the growth of cells in vitro, for example, by incubating a cancer cell culture with the derivative, and then evaluating cell growth inhibition in the culture.
Alternatively, a taxane can be tested in' vivo for antitumor activity, for example, by first establishing tumors in suitable test animals, e.g., immune-deficient mice such as SCID mice, administering the taxane to the animals and then measuring tumor growth inhibition and survival rates. Cells suitable for such in vitro or in vivo testing include, without limitation: murine P388 leukemia, B16 melanoma and Lewis lung cancer cells; human breast carcinoma MCF7, human MCF-7/ADR
(adriamycin-resistant), human ovarian OVCAR-3, human HT-29 colon carcinoma and A549 human lung carcinoma cells; and other cells generally accepted in the art for such~testing, including those -~ a-cells which are drug-resistant. Ordinarily skilled artisans given the teachings of this invention are well able to select particular taxanes for application against certain cancers, on the basis of such factors as Glso, EDSO, survival rates and other data derived from routine in vitro or in vivo N
experimentation °Anticancer effective amounts" of a taxane are any amount of the taxane effective to ameliorate, lessen, inhibit or prevent the establishment, growth, metastasis, invasion or spread of a cancer, and can be the same amount as therapeutic doses of the corresponding free taxane. However, the attachment of an HPG-derivatized acyl chain to a taxane and the association of this taxane with a lipid carrier can enhance the taxane's therapeutic index.
Thus, anticancer effective amounts of this derivatized acyl chain-taxane can also be less than those of the corresponding free taxane. Taxane anticancer effective amounts can be chosen in accordance with a number of factors, e.g., the age, size and general condition of the subject, the cancer being treated and the intended route of administration of the derivative, and determined by a variety of means, for example, dose ranging trials, well known to, and readily practiced by, ordinarily skilled artisans given the teachings of this invention. Generally, the anticancer effective amount of the taxane is at least about 0.1 mg of the taxane per kg of body weight c' the animal to which the taxane-containing composition is administered. Typically, the anticancer eitective amount of the taxane is from about 0.1 mg per kg of body weight of the animal to about 1000 mg per kg; preferably, the anticancer effective amount is from about 1 mg per kg to about 200 mg per kg.
Preferably, taxane-containing compositions provided herein also comprise a lipid carrier, more preferably, a liposome and most preferably a unilamellar liposome having a diameter of less than about 200 nm. Preferred anticancer taxanes have A~ being the group C6H$C(O)NHCH(C6H5)CH(OR)C(O)-, AZ being CH3C(O)- and A3 being H, i.e., are paclitaxels.
At least one of R or R' is preferably -C(O)CHX'(CH2)3CH3, -C(O)CHX'(CHZ)SCH3, -C(O)CHX'(CHz)9CH3, -C(O)CHX'(CHZ)~~CH3 or -C(O)CHX'(CHZ)~3CH3, with X' preferably being F, CI, Br or I.
Tables 3 and 4 (below) present results showing the acute toxicity of paclitaxel or the paclitaxel derivative in the mice, that is, the number of mice in each treatment group that died within the first 14 days post-injection. The results show that both of the paclitaxel derivative-containing liposomes were less toxic than were the paclitaxel-containing liposomes, with all five of the mice in the group receiving 100 mg per kg paclitaxel dying within the first 14 days.
2-Bromo-C16 paclitaxel (paclitaxel to which a sixteen-carbon acyl chain has been attached at the 2' position, the acyl chain being derivatized by the substitution of a bromine atom for an alpha carbon hydrogen atom) derivative-containing liposomes were less toxic than were the 2-bromo-C6 paclitaxel derivative-containing liposomes. Tables 3 and 4 (below) present results showing the acute Toxicity of paclitaxel or the pacfitaxel derivative in the mice, that is. the number of mice in each treatment group that died within the first 14 days post-injection. The results show that both of the paciitaxel derivative-containing liposomes were less toxic than were the paclitaxel-containing liposomes, with aft five of the mice in the group receiving 100 mg per kg paciitaxel dying within the first 1~4 days. 2-Bromo-C16 paclitaxel demiative (paciitaxel derivatized with a 16-carbon hexanoyi chain to whioh has teen attached a bromine atom on the alpha carbon)-containing liposomes were less toxic than were the 2-bromo-C6 paciitaxel derivative-containing liposomes. Moreover, iiposomes cornaining either paciitaxel or a 2'(2-bromo) hydrophobic paclitaxel derivative (containing either a six-carbon (C-6), G8, C-12, C-14 or C-16 aryl chain at the 2' position) ware administered, i!ntraperitoneally in 5 doses, to scid (severe combined immunodeficiency) mice bearing a human ovarian cancer (~OvCar 3), at a dose of 12.5 m paclitaxel per kg or a dose of 50 paclitaxel derivative per kg. Results of this treatment are presented in Figure 1, in terms of days of mouse survival pose administration of either paclitaxel or a paciitaxel derivative. These results clearly show that treatment with a paclitaxel derivative extended the fife span of the mice, in comparison to treatment either with paclitaxel itself or with air 'empty" liposame, i.e.. a iiposome containing neither paclitaxel or a paclitaxel derivative. Moreover, paditaxel derivatives having aryl chains of increasing length were increasingly effective at extending life spans.
Furthermore, an additional bioactive agent can be administered to the animal as part of this invention's method; the additional agent is preferably, but not necessarily, a component of the taxane-containing composition, and is preferably, but not necessarily, associated with the lipid carrier when the composition contains such a carrier. Preferably, that carrier is a liposome. Liposomes can be loaded wtth bioactive agents by soiubilizing the agent in the lipid or aqueous phase used to prepare the fiposomes. Alternatively, ionizable bioactive agents can be loaded into liposomes by first fam~ing the liposomes, establishing an electrochemical potential, e.g., by way of a pH gradient, across the outermost liposomal bilayer, and then adding the ionizable agent to the aqueous medium external to the iiposome (see Belly et al.
U.S. Patent No. 5,077,056).
This invention will be better understood from the following Examples. However, those of ordinary skill in the art will readily understand that these examples are merely illustrative of the invention as defined in the claims which follow thereafter.
-1 d-EXAMPLES
Exa~le 1 Preparation of 2'-L)~2-8r~amahexanoyl l~axo!
2'-(~)-2-Bromo octanoyl, dodecanoyl, tetradecanoyl, and hexadecanoyl paclitaxels were prepared (in 80-90% yield) by the procedure explained below, and identified by the 'H
NMR and elemental analysis. To a 10 min, stirred solution of ~)-~-bromohexanoic acid (229 mg, 1.17 mmol) and 1,3-dicyclohexyl carbod'iimide (241 mg, '1.i7 mmol) in 30 mi of dry methylene chloride, was added taxolT"' (500 mg. 0.5$6 mmol) and the base 4-)0 dimethylaminopyridine (71.5 mg, 0.586 mmoi). The reaction mixture was allowed to proceed at room temperature far 5 min. The white precipitate of dicyclohexyl urea was filtered through a C:eliteT"" pad. The resultant filtrate was evaporated under vacuo and the residue obtained was purified by a preparative thin layer chromatography in CHCI~:MeOH (95:5) to give the desired product (Rr = 0.58 in CHCl3:MeOH, 95:5). After passing tt°vrough a MetricelT"' ~Itef X0.1 m) t0 remove the silica gel from the CHCI3 solution, the product was lyophilized from cyclohexane to give 507 mg (84% yield) as the white powder.
''e NMR (CDCI~. 300 MHz) chemical shifts of same of the characteristic peaks at b (in ppm): 8.14 (d, J = 7.3 Hz, 2H, aromatic), 7.72( d. J = 7.3 Hz. 2H, aromatic), 7.61 (m, 1H, aromatic). 7.54-7.48 (m, 3H, aromatic), 7.42-7.36 (m, 7H, aromatic), 6.87 (dd, J = 2.4 Hz, 3.4 Hz. 1 H, NH). 6.29 (m, 2H, H-10 and H-13), 6.0 (m, 1 H, H-3') 5.68 (d. J = 6,9 Hz, 1 H, H-2b), 5.50 (dd, J = 1.4 Hz, 1.0 Hz. 1 H, H-2'), 4.97 (d, J = 7.8 Hz, 1 H. H-5), 4.45 (m, 1 H. H-7). 4.32 (d, J = 7.3 Hz, 1 H, H-20a), 4.28 (m, 1 H, CH(Br)), 4.20 (d, J = 8.3 Hz, 1 H.
H-20b), 4.0 (br, OH), 3.81 (d, J = 6.9 Hz. 1 H, H-3), 0.86 (app. t. 3H, w-CHa). FABMS: (MN') caicd for C53H~NO,sBr 1029.32. Found 1030.
_15-scheme t: Route to the synthesis of 2'-(+~-2-Bromoacyl paditaxeis ("OCC' ~ 1,3-dicyclohexylcalbodiimide' "DMAP" = 4-dimethyfaminopyridine) .". o ~H Fatty acidIDCC H ~ c phi H . DMAP. CHZC12, Ph~" ~., Ii nun.. r1 OR' H
AcU
Paditaxd R'= ~ : R"sH
r 1.3-Dicyciol~racylarbodumde R.s : R.sH
r 4.Dimethylaminopyiidine R' ~ : R' = H
r ~~n R.s : R-sH
I r R'a : R"=H
Example 2 in Vitro Studies Table 1 (see below) shows the GI~ (~M) values (* standard deviation). that is, the concentration required for 50% growth inhibition, of various hydrolyzable taxane derivatives (NTDs) and human MCF-7 breast caranoma cells following a 72-hom ;ncubation of the cells with the HTD.
TABL~ 1 HTD CYTOTOXICiTY
Paclitaxel Derivative 2'-Hexanoyb 0.500 * 0.151 2'-2-Bromohexanoyl- 0.003 *~ 0.0002 2'-6-Bromohexanoyl- >10.000 7-Hexanoyl- 0.027 * 0.019 7-2-Bromohexanoyf- 0.0046 * 0.0001 7-6-Bromohexanoyl- 0.018 * 0.002 2'-Acety4-7-Hexanoyl- 4.46 * 0.06 2'.7-di-2-Bromohexanoyf-1.43 t 0:72 2',7-diHexanoyl- >10.00 2'-Troo-7-2-Bromohexanoyl-2.67 * 0.08 2'-Troc-7-6-Bromohexanoyl-0.47 t 0.03 "2' ' indicates attachment of an acyi chain to paaitaxel at the 2' position; T
': attachment at the T position; "bromo": derivatization of an attached acyl chain with a bromine atom.
Table 2 (see below) shows the GI~ (~M) values, averaged from two separate experiments (SRB standard cytotoxicit~r assay), for paclitaxei and various 2'-2-bromo paclitaxel derivatives and A-549 human lung carcinoma, MCF-7 human breast carcinoma, MCF-(adriamycin-resistant) and HT-29 human colon carcinoma cells following a 72-hour incubation of the cells and tiTDs C'-~-6. 8, 12. 14 and 16": 6, 8,. 12, 14 and 16-carbon acyi chains, respectively, attached to pacfitaxel).
In Vitro Sensitivity Paclitaxel 0.0023 < 0.00154.1675 < O.OOi4 f t 0.0002 0.7177 2'-2-Bromo-C6-Paclitaxel0.0039 0.0023 > 10.0000 0.0024 t 0.0008 0.0013 0.0009 2'-2-Bromo-C8-Paclitaxef0.0044 0.0029 . > 10.00000.003t t t 0.0001 0.0010 0.0003 2'-2-Brorno-C12-Paclitaxel0.0044 0.0028 > 10.0000 O.Op~
t 0.0001 0.0007 0.0002 2'-2-Bromo-C14-Paclitaxel0.0317 0.0160 >10.0000 0.0206 t t 0.0047 0.0091 0.0057 2'-2-Bromo-C16-Pacfitaxel0.1273 0.0710 >10.0000 0.0595 t t 0.0356 0.0373 0.0187 Exartmle 3 In Vivo Studies CDF1 female mice. 5 or 10 mice per group, were intn~per'rtoneally administered either paciitaxel-, 2'-C6-paclitaxel derivative-, or 2'-C16-paclitaxel derivative-containing liposomes, in a single dose, or 5 doses, of either 12.5. 25, 50, 100. 200, 300, 400 or 500 mg of paclitaxel or paclitaxel derivative per kg of mouse body weight. Tables 3 and 4 (below) present results showing the acute toxicity of paclrtaxel or the paclitaxel derivative in the mice, that is, the number of mice in each treatment group that died within the first 14 days post-injection. The results show that both of the paclitaxel derivative-containing liposomes were less toxic than were the pacl'rtaxel-containing liposomes, with all five of the mice in the group receiving 100 mg per kg paclitaxel dying w'tthin the. first 14 days. 2-Bromo-C16 paclitaxel derivative-containing liposomes were less toxic than were the 2-bromo~C6 paclitaxel detivat'rve-containing liposomes.
'TABLE 3 SINGLE DOSE ADMINISTRATION
Dose (mg/kg)Paclitaxel Pacfitaxel Derivative 2-Bromo-C6 2-Bromo-C16 400 ____- 5/5 0/5 300 _____ 5/5 1 /5 200 _____ 4/5 1 /5 100 0/2 ____ 5/5 ____ 50 _____ 0/10 _____ 25 ____ 0/10 _____ 12.5 0/10 ____ ____ FIVE DOSE ADMINISTRATION
Dose (mg/kg) Pactitaxel 2-~romo-C6 Paciitaxel Derivative 12.5 0/10 _____ Liposomes containing either paclitaxel or a 2'-(2-bromo) hydrophobic paclitaxei derivative (containing either a six-carbon (C-6), C-8, C-12, C-14 or C-16 acyl chain at the 2' position) were administered, intraperitoneally . in 5 doses, to scid (severe combined immunodeficiency) mice bearing a human ovarian cancer (OvCar 3), at a dose of 12.5 m paclitaxel per kg or a dose of 50 paclitaxel derivative per kg. Results~of this treatment are presented in Figure 1, in terms of days of mouse survival post administration of either paclitaxel or a paclitaxel derivative. These results clearly show that treatment with a paclitaxel derivative extended the life span of the mice, in comparison to treatment either with paclitaxel itself or with an 'empty' liposome, i.e., a liposome containing neither paclitaxel or a paclitaxel derivative. Moreover, paclitaxel derivatives having acyl chains of increasing length were increasingly effective at extending life spans.
_18_
This invention provides a taxane having the formula:
A~ O' 5 A~ is H or a group having the fom~uia Z~C(O)NHCH(C,Hs)CH(OR)C(O)-, A~ is H
or CHsC(O)-, and A~ is H or OH. Z is CdHs, CdHsCH2-O-. C(CHs)r0- or CH(CH')=C(CH~-~ Most preferably.
A~ is CaHsC(O)NHCH(CsHs)CH(OR)C(O}-, A~ is CH'C(O)- and A~ ~ H. Accordingly, the .
taxane most preferred herein is a paditaxel ([Cort>pound f); TAXOL~ (C"Hs,NO), l3ristd-Myers Squibb) derivative.
Howe~t, '"' 111)~based derivatives, which differ from pad'rtaxel by having a tsrt-brrtoxy carbonyl group at the C-12 position, instead of a bertzoyl gn~up, and a hydroxyl group, instead of an acetyloxy group, at C-10 are also provided heroin. Aocadingly, fnr taxotereT", Al is C(CHI)~OC(O)NHCH(C,HS)CH(OR)G(O)-, A2 is H, and As is H.
Further taxanes useful in accordance with the practice of this invention irxlude, without limitation: Cephalomannine (111); 19-hydroxybaccatin III [IVJ, Baa~tin V (Vj.
10-deacetyl cephalomannine [VI], 10-deacetyl paclitaxel [YIIj, 7~lpi-10-deacetyl paditaxel (Vltlj, 7-Epi-10-deacetyl cephalomannine [17C], and 10-deacetyl baccatin Ill (X], as described in the following 20 table.
_5.
Compound 1 p PactitaxelC6HSC(O)NHCN(CBHs) CH M
C(O)-(I) CH(OR)C(O)- ~
TaxotereT"'C(CH3)3OC(O)NHCH H H
(11) (C6H~)CH(OR)C(O)-Cephalo- (CH3)CH=C(CH9)C(O)NHCHCH3C(O)- H
i mann (CgH$)CH(OR)C(O)-ne (111) 19-hydroxyH
CH3C(O). OH
baccatin III
(IV) Baccatin H CH H
III C(O)-10-Deacetyl(CH~)CH=C(CH3)C(O) H H
cephalo NHCH(C
H
)CH(OR) C(O)-mannine 6 (VI) ceryi C'HsC(O)NHCH(C M H
e H
) taxol 6 "' 6 CH(OR)C(O).
(VII) (7a-OH) 7-Epi-10-C6HSC(O)NHCH(C H H
H
) deaceNi 6 ~
~,H(OR)C(O)-ta~cOIT"'(7~-OH) (VIII) 7-Epi-10- (CH3)CH=C(CH~)C(O) H H
deacetyi NHCH(C6Hs)CH(OR)C(O)-cephalo mannme(7~-OH) (IX) 10-Deacetyl H H H
baccatin III
(X) Each of R and R' is H or a graup having the formula -Y'Y2, provided that at least one of R and R' is not H. Y' is the group -C(O)CHX'(CH2)"~(CH=CH)n2(CH2)"s(CH=CH)nalCl"(a)"x(CH=CH)"s(CHz)"~(CH=CH)"e (CHZ)n9~-~ The sum of n1 +2n2 + n~ + 2n4 + n~ + 2n6 + n~ + 2n8 + ng+ is an integer of from 1 to 21, -~,-wherein each of n2, n4, n6 and n8 is independently zero or 1. n1 is equal to zero or an integer of from 1 to 21, n3 is equal to zero or an integer of from 1 to 18, n5 is equal to zero or an integer of from 1 to 15, n7 is equal to zero or an integer of from 1 to 12, and n9 is equal to zero or an integer of from 1 to 9. Each of ni to n9 can be the same or different at each occurrence.
Preferably, Y' is saturated, that is, there are no double bonds between adjacent carbon atoms.
Accordingly, n2, n4, n6 and n8 are each preferably zero, n3, n5, n7 and n9 are each also zero, and Y~ is preferably -C(O)CHX'(CH2)~~-. Alternatively, Y' can be unsaturated, that is, it can have one or more double bonds and one or more CH=CH units; accordingly, at least one of n2, n4, n6 and n8 is then 1. For example, when the unsaturated acyl chain has one double bond: n2 is 1, n4, n6 and n8 each being zero; Y~ is then -C(O)CHX'(CHZ)~~CH=CH(CH2)~ ; ni is zero or an integer from 1 to 18; n3 is also zero or an integer from 1 to 18, at feast one of ni or n3 is not zero, and the sum of n1 plus n3 is equal to an integer of from 1 to 19.
Y2 is preferably -CH3, the acyl chain thus being derived from a monocarboxylic acid, but can also be -COZH, the acyl chain being derived from an omega dicarboxylic acid, or -CHZOH, the acyl chain then being derived from an omega hydroxy acid.
Accordingly, the group Y'Y2 preferably has the formula -C(O)CHX'(CHZ)"~CH3, wherein n1 is most preferably equal to 3, 5, 9, 11 or 13, whether the group be located at R, R' or both R
and R'.
"Attachment" of the group -Y'Y2 to a taxane means forming a chemical connection between the group and the taxane by any means generally accepted in the art for forming such connections. Attachment is to one or more reactive groups, typically hydroxy groups, on the taxane. Attachment of any acyl chain to a taxane can stabilize the taxane-lipid carrier association, such that the taxane an carrier remain together, for example, in the plasma of animals for a longer period of time than does the corresponding acyl chain-free taxane.
Increased stability of association enhances the amount of the taxane reaching its intended site of therapeutic action in vivo.
Paclitaxel, for example, has two hydroxyl groups to which acyl chains can be attached;
these are located at the 2' and 7 positions, with their relative order of reactivity generally believed to be (from most reactive to least reactive) 2'>7. Hydrocarbons can be attached to the primary reactive group of a taxane, e.g., the 2' OH group of paclitaxel, utilizing stoichiometric amounts of the an active form of the acid, e.g., chlorides or anhydrides. The hydroxyl group at the 7 position of paclitaxel can be modified by attaching an acyl chain to both the 2' and 7 OH groups, and then selectively removing the 2' acyl chain so that the acyl chain at the 7 position remains attached to paclitaxel. Selective removal of the 2' acyl chain can be accomplished using stoichiometric amounts of a mild base, e.g., sodium bicarbonate.
_7_ Additionally, the 7 OH group of paclitaxel can be modfied by "protecting" the 2' OH gn~p before covalently linking paclitaxel with the acyl chain. The 2' OH group can also be protected with groups such as, for example, triphenyl methyl, methoxytriphenyl methyl, fifiuoroacetyl and TrOC (trichloromethoxy chlorofortnatej groups, using processes generally known to ordinarily skilled artisans. The protected paclitaxel is then reacted with an active form of the acyl chain, e.g., anhydrides or chlorides, in anhydrous organic sohrent, and bases such as DMAP and pyridine. The protecting group can be removed from the 2' position by well known and readily practiced means, under mildly acidic or basic conditions: TtOC groups, for example, can be removed by zinc reduction reactions.
1O' Reactions are typically perforated in the presence of a base, such as pyridine, dimethylaminopyridine ("DMAP"y. triethytamine, or others, and in common polar, aprotic organic solvents such as dimethyl fotmamide: dimethyl sulfoxide and the bke.
The progress of the reaction can be monitored by a number of well known chromatographic means, for example, thin layer chromatography using a 3% methanol-in-chloroform solvent system. The compound's identity can be confimted by spectroscopic proceduros, such es NMR
spectroscopy.
For example, the following reaction scheme, and the infomtation described bek~nr, can be used to prepare 2'-(~-2-8'omoacyl paclitaxels:
Leo O OH ADO
r r Fatty acitltDCC O O
off DMAP. CHZCIy Ph J
=~ IS trtin, r.t. ~ OR' =AeD
PhtOb O
R'= ~ : R"sH
r 1.3-Dieyebtiexylcarbodiitude R. a ~ ; R-. H
O r R.a ; R"sH
s.Dimethylaminopy~asne r NICFt;)z R~a rwW.: R"all Or R~= ; R"all However: specific reaction and purificatwn conditions are generally expedsd to vary according to a number of factors, including without limitation, the raw materials and reactants used, that are well within the purview of ordinarily skilled artisans to determine and control given the teachings of this invention.
Acyl chains substituted with a hydrolysis-promoting group on the alpha carbon can be purchased from commercially available sources, or synthesized according to any of the means . generally accepted in the art for substitution of a hydrogen atom on the alpha carbon of a fatty acid.
"Hydrolysis-promoting-groups" ("HPGs") are substitutions at an acyl chain's alpha carbon (Ca) that promote hydrolysis of the bonds between a parent taxanes its attached acyl chain. HPGs are electronegative relative to hydrogen, meaning that they draw electrons to themselves more than a hydrogen atom would if it occupied the same position in the same molecule. Accordingly, substitution of a hydrolysis-promoting group for a hydrogen atom on the alpha carbon results in a redistribution of an acyl chain's electron density, and thereby causes an inductive effect in the acyl chain. Substitution of aromatic moiety-containing HPGs for alpha carbon-attached hydrogens can also cause resonance effects, these too involving electron density redistribution in the substituted acyl chain. HPG-induced induction and resonance effects stabilize an acid's corresponding base form, but not the acid itself, and thereby causes the acid to be a stronger acid than it would be if there was a CH2 group in the acyl chain instead of the HPG. HPG-substituted acyi chains thus generally have lower pK,'s than their corresponding native forms, that is, the form in which a CHz group is present at the alpha position instead of an HPG-substituted group, and hence, HPG-substituted acyl chains' are more readily hydrolyzable from their parent taxanes than are nonsubstituted chains.
Accordingly, the hydrolysis-promoting group X' can be any atom or group of atoms: (1) having an electronegativity greater than hydrogen; and, (2) that can be attached at the alpha position of an acyl chain. X' can, for example, be F, CI, Br, I, NH3*, the group -OCsH4X2 or the group C(O)X2; XZ is, for example, F, CI, Br, I, NH3*, NOZ or CN. Preferably, X' is F, CI, Br or 1.
Also provided herein is a composition comprising a taxane of this invention.
Compositions intended for therapeutic use of the taxane preferably also comprise a pharmaceutically acceptable medium, which is a medium generally intended for use in connection with the administration of active ingredients, such as therapeutic or diagnostic agents, to animals. These include, without limitation: solids, such as pills, capsules and tablets; gels; excipients; and aqueous or nonaqueous solutions.
Pharmaceutically acceptable media are generally formulated according to a number of factors well within the purview of the orciinarily skilled artisan to determine and account for, including without limitation: the particular - active ingredient used, its concentration, stability and intended bioavailability; the disease, disorder or condition being treated with the composition; the subject, its age, size and general cond'ttion: and the composition's intended route of administration, e.g..
nasal, oral, ophthaunic, topical, transdermal, vaginal. subcutaneous, intramammary, intraperrtoneal, intravenous, or intramuscular (see, for example. J. G. Naim, in: R~,minrrton's Pharmaceutical Science (A.
Gennaro, ed.), Mack Publishing tyo., Easton, PA, (1985), pp. 1492-1517).
Typical pharmaceutically acceptable media used in parenterai drug administration include, for example, DSW, an aqueous solution containing S°/a weight by volume of dextrose, and physiological saline.
Texans-containing compos'ttion6 provided herebn prefet~ comprwse a . lipid carrier with which the taxane is associated, "Lipid carriers" are hydrophobic or annphipathic molecules suitable for administration to animals, and include, without limitation: fatty acids, phosphalipids, micelles, lipoproteins, lipid complexes, i.e., nonliposomal, lipid-based structures which may, but are not required to contain one or more nanlipid components, and liposomes. Preferably, the lipid carrier is a tiposome.
"Liposomes" comprise one or more bilayers of lipid molecules, each biiayer encompassing an aqueous compartment. Unitamellar liposomes have a single lipid bilayer, and multilamellar liposomes have more than one bilayer. The amphipathic lipid molecules which make up lipid bilayers comprise a paler (hydrophilic) headgroup and one or two aryl chains. The polar groups can be phosphate-> sulfate- or nitrogen-based groups, but are preferably phosphate groups, such as phosphorylcholine, phosphoryiethanolamine, phosphorylserine, phosphorylglycerol or phosphorylinositol groups. The acyl chains generally comprise from 12 to 24 carbon atoms, and can be saturated (e.g., lauric, mytistic, palmftic, or stearic acid), or unsaturated (e.g., oleic, linaleic, linolenic, or arachidonic acid). Liposomal lipid can also include sterols, such as cholesterol, and other IipHds.
Liposomes can be made by a variety of methods, including: f3angham's methods for making multilamellar liposomes (MLVs) invohring drying of a lipid/organic solvent solut'ron and then rehydrating the dried lipids with an aqueous solution (see Bangham et al., 1965); Lenk's, method for making MLVs wrth substantially equal interiamellar solute distribution (SPLVs) involving forming a. biphasic mixture tat an aqueous phase end a lipid-containing organic phase, and then emulsifying the lipid in the aqueous phase while evaporating the organic (see U.S. Patent Nos. 4,522,803, 5,030,453, and 5.~69,fi37); Fountain's (U.S.
Patent No.
x.588,578) method of making SPLVs using a monophasic solvent system; Cullis' (U.S. Patent No. 5,008,050) method of making SPLVs using repeated cycles of treezing and thawing;
preparation of REVs through tormation of a water-in-oil emulsion, from which the organic phase is evaporated to give a gel, the gel then being agitated to give oligolamellar liposames (see Papahadjopoulos et al., U.S. Patent No. 4,235.871 ); extrusion of MLVs to make unilamellar liposomes (see, e.g., Cullis et al., U,S. Patent No. 4,975,282);
as well as sonication or homogenization of larger liposomes, or ether or ethanol injection processes (see, for example, R. Dearrter and P. Uster, "Liposome Preparation:
Methods and Mechanisms," in Linoso n ~ (M. C7stra, ed.), Marcel Dekker, Inc., New 'York (1983), pp.27-52).
"Association" as used herein generaltyr means association between the aryl chain attached to the taxane and the hydrophobic portion of the lipid tamer. Without intending to be limtted by theory, it is believed that such association is by way of a number of influences, such as Van der Weal's forces, generally known to operate between hydrophobic malecules in an aqueous environment. Means of determining the stability of such associations, for example.
by determining the percentage of taxane recoverable with phosphorous when the lipid tarsier comprises a phospholipid are readily practiced by ordinarily skilled artisans given the teachings of this invention.
Lipid tamers associated with the taxane of this invention can comprise an additional bioactive agent, that is, a bioactive agent in addft'ron to the taxane. Lipid carrierlbioact'rve agent formulations can enhance the therapeutic index of the bioactive agent, for example by buffering the agent's toxicity and by reducing the rate at which the agent is cleared from the ciroulation of animals, thereby meaning that less of the agent need be administered to achieve the desired therapeutic effect. "Bioactive agents" are compounds or compositions of matter having biological activity on animal cells in vtro or when administered to an animal; bioactive agents can have therapeutic andlor diagnostic activity. Such agents include, but are not limited to, antimiccobial, anti-inflammatory and anticancer agents as well as radioactive isotopes, enzymes and dyes. Additional bioactive agents also include bioackive lipids, such as certain ceramides and ether lipids, which themselves have therapeutically beneficial properties. Preferably, the addttional bioactrve agent is an anticancer agent.
Lipid carriers can also comprise one or more "headgroup-mortified lipids."
These comprise polar groups derivatized by attachment thereto of a moiety which can inhib'tt the binding of serum proteins to headgroup-modified lipid-containing lipid carriers. This afters the pharmacokinetic behavior of the carriers such that they remain in circulation longer (see, e.g., Blume et al., Biochim. Biophys. Acta. 114 :180 (1993): Gabizon et al., Pharm.
Res. x,0_(5):703 (1993): Park et at. Biochim. Biophys Acta. ~Q~:257 (1992); Woodie et al., U.S.
Patent No.
5.013.556; Allen et al., U.S. Patent Nos. 4,837,028 and 4,920,016).
_f1_ Headgroup-modified lipids are typically phosphatidylethanoiamines (PE's), for example dipalmitoyl phosphatidylethanoiamine (°DPPE°), palmitoyloteoyl phosphatidylethanoiamine ("POPE") and dioleoyl phosphatidylethanolamine ("DOPE"), amongst others. Such lipids have headgroups generally derivatized with organic dicarboxyiic acids, such as succinic or gfutaric ,.
acid ("GA"), or their corresponding anhydrides.
The amount of the headgroup-modified lipid incorporated into the lipid carrier generally depends upon a number of factors well known to the ordinarily skilled artisan, or within his purview to determine without undue experimentation. These include, but are not limited to: the type of lipid and the type of headgroup modification; the type and size of the carrier; and the intended therapeutic use of the formulation. Typically, from about 5 mole percent to about 20 mote percent of the lipid in a headgroup-modified lipid-containing lipid carrier is headgroup-modified lipid.
Further provided herein is a method of administering a taxane to an animal, which comprises administering the composition of this invention to the animal, preferably a mammal such as a human. Administration is by any other means generally accepted for administration of therapeutic agents to animals, but is preferably intravenous or intraperitoneal. Animals afflicted with cancers can be treated by therapeutic administration of taxane-containing compositions, wherein the compositions comprise an anticancer effective amount of a taxane.
Generally, those cancers treatable by this method are those which are, or may be, treated with the corresponding free taxane, i.e., a taxane not having an attached acyl chain.
These include, without limitation: brain, breast, colon, lung, ovarian, prostate, pancreatic and stomach cancers; as well as, leukemias, lymphomas, sarcomas and carcinomas.
Preferably, the treated cancer is a breast or ovarian cancer. The cancer treated can be a cancer that is resistant to standard therapeutic regimens, i.e., a drug-resistant cancer.
A taxane's anticancer activity can be determined by examining the taxane's ability to inhibit the growth of cells in vitro, for example, by incubating a cancer cell culture with the derivative, and then evaluating cell growth inhibition in the culture.
Alternatively, a taxane can be tested in' vivo for antitumor activity, for example, by first establishing tumors in suitable test animals, e.g., immune-deficient mice such as SCID mice, administering the taxane to the animals and then measuring tumor growth inhibition and survival rates. Cells suitable for such in vitro or in vivo testing include, without limitation: murine P388 leukemia, B16 melanoma and Lewis lung cancer cells; human breast carcinoma MCF7, human MCF-7/ADR
(adriamycin-resistant), human ovarian OVCAR-3, human HT-29 colon carcinoma and A549 human lung carcinoma cells; and other cells generally accepted in the art for such~testing, including those -~ a-cells which are drug-resistant. Ordinarily skilled artisans given the teachings of this invention are well able to select particular taxanes for application against certain cancers, on the basis of such factors as Glso, EDSO, survival rates and other data derived from routine in vitro or in vivo N
experimentation °Anticancer effective amounts" of a taxane are any amount of the taxane effective to ameliorate, lessen, inhibit or prevent the establishment, growth, metastasis, invasion or spread of a cancer, and can be the same amount as therapeutic doses of the corresponding free taxane. However, the attachment of an HPG-derivatized acyl chain to a taxane and the association of this taxane with a lipid carrier can enhance the taxane's therapeutic index.
Thus, anticancer effective amounts of this derivatized acyl chain-taxane can also be less than those of the corresponding free taxane. Taxane anticancer effective amounts can be chosen in accordance with a number of factors, e.g., the age, size and general condition of the subject, the cancer being treated and the intended route of administration of the derivative, and determined by a variety of means, for example, dose ranging trials, well known to, and readily practiced by, ordinarily skilled artisans given the teachings of this invention. Generally, the anticancer effective amount of the taxane is at least about 0.1 mg of the taxane per kg of body weight c' the animal to which the taxane-containing composition is administered. Typically, the anticancer eitective amount of the taxane is from about 0.1 mg per kg of body weight of the animal to about 1000 mg per kg; preferably, the anticancer effective amount is from about 1 mg per kg to about 200 mg per kg.
Preferably, taxane-containing compositions provided herein also comprise a lipid carrier, more preferably, a liposome and most preferably a unilamellar liposome having a diameter of less than about 200 nm. Preferred anticancer taxanes have A~ being the group C6H$C(O)NHCH(C6H5)CH(OR)C(O)-, AZ being CH3C(O)- and A3 being H, i.e., are paclitaxels.
At least one of R or R' is preferably -C(O)CHX'(CH2)3CH3, -C(O)CHX'(CHZ)SCH3, -C(O)CHX'(CHz)9CH3, -C(O)CHX'(CHZ)~~CH3 or -C(O)CHX'(CHZ)~3CH3, with X' preferably being F, CI, Br or I.
Tables 3 and 4 (below) present results showing the acute toxicity of paclitaxel or the paclitaxel derivative in the mice, that is, the number of mice in each treatment group that died within the first 14 days post-injection. The results show that both of the paclitaxel derivative-containing liposomes were less toxic than were the paclitaxel-containing liposomes, with all five of the mice in the group receiving 100 mg per kg paclitaxel dying within the first 14 days.
2-Bromo-C16 paclitaxel (paclitaxel to which a sixteen-carbon acyl chain has been attached at the 2' position, the acyl chain being derivatized by the substitution of a bromine atom for an alpha carbon hydrogen atom) derivative-containing liposomes were less toxic than were the 2-bromo-C6 paclitaxel derivative-containing liposomes. Tables 3 and 4 (below) present results showing the acute Toxicity of paclitaxel or the pacfitaxel derivative in the mice, that is. the number of mice in each treatment group that died within the first 14 days post-injection. The results show that both of the paciitaxel derivative-containing liposomes were less toxic than were the paclitaxel-containing liposomes, with aft five of the mice in the group receiving 100 mg per kg paciitaxel dying within the first 1~4 days. 2-Bromo-C16 paclitaxel demiative (paciitaxel derivatized with a 16-carbon hexanoyi chain to whioh has teen attached a bromine atom on the alpha carbon)-containing liposomes were less toxic than were the 2-bromo-C6 paciitaxel derivative-containing liposomes. Moreover, iiposomes cornaining either paciitaxel or a 2'(2-bromo) hydrophobic paclitaxel derivative (containing either a six-carbon (C-6), G8, C-12, C-14 or C-16 aryl chain at the 2' position) ware administered, i!ntraperitoneally in 5 doses, to scid (severe combined immunodeficiency) mice bearing a human ovarian cancer (~OvCar 3), at a dose of 12.5 m paclitaxel per kg or a dose of 50 paclitaxel derivative per kg. Results of this treatment are presented in Figure 1, in terms of days of mouse survival pose administration of either paclitaxel or a paciitaxel derivative. These results clearly show that treatment with a paclitaxel derivative extended the fife span of the mice, in comparison to treatment either with paclitaxel itself or with air 'empty" liposame, i.e.. a iiposome containing neither paclitaxel or a paclitaxel derivative. Moreover, paditaxel derivatives having aryl chains of increasing length were increasingly effective at extending life spans.
Furthermore, an additional bioactive agent can be administered to the animal as part of this invention's method; the additional agent is preferably, but not necessarily, a component of the taxane-containing composition, and is preferably, but not necessarily, associated with the lipid carrier when the composition contains such a carrier. Preferably, that carrier is a liposome. Liposomes can be loaded wtth bioactive agents by soiubilizing the agent in the lipid or aqueous phase used to prepare the fiposomes. Alternatively, ionizable bioactive agents can be loaded into liposomes by first fam~ing the liposomes, establishing an electrochemical potential, e.g., by way of a pH gradient, across the outermost liposomal bilayer, and then adding the ionizable agent to the aqueous medium external to the iiposome (see Belly et al.
U.S. Patent No. 5,077,056).
This invention will be better understood from the following Examples. However, those of ordinary skill in the art will readily understand that these examples are merely illustrative of the invention as defined in the claims which follow thereafter.
-1 d-EXAMPLES
Exa~le 1 Preparation of 2'-L)~2-8r~amahexanoyl l~axo!
2'-(~)-2-Bromo octanoyl, dodecanoyl, tetradecanoyl, and hexadecanoyl paclitaxels were prepared (in 80-90% yield) by the procedure explained below, and identified by the 'H
NMR and elemental analysis. To a 10 min, stirred solution of ~)-~-bromohexanoic acid (229 mg, 1.17 mmol) and 1,3-dicyclohexyl carbod'iimide (241 mg, '1.i7 mmol) in 30 mi of dry methylene chloride, was added taxolT"' (500 mg. 0.5$6 mmol) and the base 4-)0 dimethylaminopyridine (71.5 mg, 0.586 mmoi). The reaction mixture was allowed to proceed at room temperature far 5 min. The white precipitate of dicyclohexyl urea was filtered through a C:eliteT"" pad. The resultant filtrate was evaporated under vacuo and the residue obtained was purified by a preparative thin layer chromatography in CHCI~:MeOH (95:5) to give the desired product (Rr = 0.58 in CHCl3:MeOH, 95:5). After passing tt°vrough a MetricelT"' ~Itef X0.1 m) t0 remove the silica gel from the CHCI3 solution, the product was lyophilized from cyclohexane to give 507 mg (84% yield) as the white powder.
''e NMR (CDCI~. 300 MHz) chemical shifts of same of the characteristic peaks at b (in ppm): 8.14 (d, J = 7.3 Hz, 2H, aromatic), 7.72( d. J = 7.3 Hz. 2H, aromatic), 7.61 (m, 1H, aromatic). 7.54-7.48 (m, 3H, aromatic), 7.42-7.36 (m, 7H, aromatic), 6.87 (dd, J = 2.4 Hz, 3.4 Hz. 1 H, NH). 6.29 (m, 2H, H-10 and H-13), 6.0 (m, 1 H, H-3') 5.68 (d. J = 6,9 Hz, 1 H, H-2b), 5.50 (dd, J = 1.4 Hz, 1.0 Hz. 1 H, H-2'), 4.97 (d, J = 7.8 Hz, 1 H. H-5), 4.45 (m, 1 H. H-7). 4.32 (d, J = 7.3 Hz, 1 H, H-20a), 4.28 (m, 1 H, CH(Br)), 4.20 (d, J = 8.3 Hz, 1 H.
H-20b), 4.0 (br, OH), 3.81 (d, J = 6.9 Hz. 1 H, H-3), 0.86 (app. t. 3H, w-CHa). FABMS: (MN') caicd for C53H~NO,sBr 1029.32. Found 1030.
_15-scheme t: Route to the synthesis of 2'-(+~-2-Bromoacyl paditaxeis ("OCC' ~ 1,3-dicyclohexylcalbodiimide' "DMAP" = 4-dimethyfaminopyridine) .". o ~H Fatty acidIDCC H ~ c phi H . DMAP. CHZC12, Ph~" ~., Ii nun.. r1 OR' H
AcU
Paditaxd R'= ~ : R"sH
r 1.3-Dicyciol~racylarbodumde R.s : R.sH
r 4.Dimethylaminopyiidine R' ~ : R' = H
r ~~n R.s : R-sH
I r R'a : R"=H
Example 2 in Vitro Studies Table 1 (see below) shows the GI~ (~M) values (* standard deviation). that is, the concentration required for 50% growth inhibition, of various hydrolyzable taxane derivatives (NTDs) and human MCF-7 breast caranoma cells following a 72-hom ;ncubation of the cells with the HTD.
TABL~ 1 HTD CYTOTOXICiTY
Paclitaxel Derivative 2'-Hexanoyb 0.500 * 0.151 2'-2-Bromohexanoyl- 0.003 *~ 0.0002 2'-6-Bromohexanoyl- >10.000 7-Hexanoyl- 0.027 * 0.019 7-2-Bromohexanoyf- 0.0046 * 0.0001 7-6-Bromohexanoyl- 0.018 * 0.002 2'-Acety4-7-Hexanoyl- 4.46 * 0.06 2'.7-di-2-Bromohexanoyf-1.43 t 0:72 2',7-diHexanoyl- >10.00 2'-Troo-7-2-Bromohexanoyl-2.67 * 0.08 2'-Troc-7-6-Bromohexanoyl-0.47 t 0.03 "2' ' indicates attachment of an acyi chain to paaitaxel at the 2' position; T
': attachment at the T position; "bromo": derivatization of an attached acyl chain with a bromine atom.
Table 2 (see below) shows the GI~ (~M) values, averaged from two separate experiments (SRB standard cytotoxicit~r assay), for paclitaxei and various 2'-2-bromo paclitaxel derivatives and A-549 human lung carcinoma, MCF-7 human breast carcinoma, MCF-(adriamycin-resistant) and HT-29 human colon carcinoma cells following a 72-hour incubation of the cells and tiTDs C'-~-6. 8, 12. 14 and 16": 6, 8,. 12, 14 and 16-carbon acyi chains, respectively, attached to pacfitaxel).
In Vitro Sensitivity Paclitaxel 0.0023 < 0.00154.1675 < O.OOi4 f t 0.0002 0.7177 2'-2-Bromo-C6-Paclitaxel0.0039 0.0023 > 10.0000 0.0024 t 0.0008 0.0013 0.0009 2'-2-Bromo-C8-Paclitaxef0.0044 0.0029 . > 10.00000.003t t t 0.0001 0.0010 0.0003 2'-2-Brorno-C12-Paclitaxel0.0044 0.0028 > 10.0000 O.Op~
t 0.0001 0.0007 0.0002 2'-2-Bromo-C14-Paclitaxel0.0317 0.0160 >10.0000 0.0206 t t 0.0047 0.0091 0.0057 2'-2-Bromo-C16-Pacfitaxel0.1273 0.0710 >10.0000 0.0595 t t 0.0356 0.0373 0.0187 Exartmle 3 In Vivo Studies CDF1 female mice. 5 or 10 mice per group, were intn~per'rtoneally administered either paciitaxel-, 2'-C6-paclitaxel derivative-, or 2'-C16-paclitaxel derivative-containing liposomes, in a single dose, or 5 doses, of either 12.5. 25, 50, 100. 200, 300, 400 or 500 mg of paclitaxel or paclitaxel derivative per kg of mouse body weight. Tables 3 and 4 (below) present results showing the acute toxicity of paclrtaxel or the paclitaxel derivative in the mice, that is, the number of mice in each treatment group that died within the first 14 days post-injection. The results show that both of the paclitaxel derivative-containing liposomes were less toxic than were the pacl'rtaxel-containing liposomes, with all five of the mice in the group receiving 100 mg per kg paclitaxel dying w'tthin the. first 14 days. 2-Bromo-C16 paclitaxel derivative-containing liposomes were less toxic than were the 2-bromo~C6 paclitaxel detivat'rve-containing liposomes.
'TABLE 3 SINGLE DOSE ADMINISTRATION
Dose (mg/kg)Paclitaxel Pacfitaxel Derivative 2-Bromo-C6 2-Bromo-C16 400 ____- 5/5 0/5 300 _____ 5/5 1 /5 200 _____ 4/5 1 /5 100 0/2 ____ 5/5 ____ 50 _____ 0/10 _____ 25 ____ 0/10 _____ 12.5 0/10 ____ ____ FIVE DOSE ADMINISTRATION
Dose (mg/kg) Pactitaxel 2-~romo-C6 Paciitaxel Derivative 12.5 0/10 _____ Liposomes containing either paclitaxel or a 2'-(2-bromo) hydrophobic paclitaxei derivative (containing either a six-carbon (C-6), C-8, C-12, C-14 or C-16 acyl chain at the 2' position) were administered, intraperitoneally . in 5 doses, to scid (severe combined immunodeficiency) mice bearing a human ovarian cancer (OvCar 3), at a dose of 12.5 m paclitaxel per kg or a dose of 50 paclitaxel derivative per kg. Results~of this treatment are presented in Figure 1, in terms of days of mouse survival post administration of either paclitaxel or a paclitaxel derivative. These results clearly show that treatment with a paclitaxel derivative extended the life span of the mice, in comparison to treatment either with paclitaxel itself or with an 'empty' liposome, i.e., a liposome containing neither paclitaxel or a paclitaxel derivative. Moreover, paclitaxel derivatives having acyl chains of increasing length were increasingly effective at extending life spans.
_18_
Claims (30)
1. A taxane having the formula:
wherein:
A1 is H or a group having the formula Z-C(O)NHCH(C6H5)CH(OR)-C(O)-, A2 is H or CH3C(O)- and A3 is H or OH;
Z is C6H5-, C6H5CH2-O-, C(CH3)3-O- or CH(CH3)=C(CH3)-;
each of R and R1 is H or a group having the formula Y1Y2, provided that at least one of R and R1 is not H and provided that when A1 is H, R1 is not H;
Y1 is -C(O)CHX1(CH2)n1(CH=CH)n2(CH2)n3(CH=CH)n4(CH2)n5 (CH=CH)n6(CH2)n7(CH=CH)n8(CH2)n9-;
the sum of n1 + 2n2 + n3 + 2n4 + n5 +2n6 +n7 +2n8 + n9 is an integer of from 1 to 21, each of n2, n4, n6 and n8 is independently zero or 1, n1 is zero or an integer of from 1 to 21, n3 is zero or an integer of from 1 to 18, n5 is zero or an integer of from 1 to 15, n7 is zero or an integer of from 1 to 12, n9 is zero or an integer of from 1 to 9 and each of n1 to n9 can be the same or different at each occurrence;
X1 is an hydrolysis-promoting group which exhibits an electronegativity greater than hydrogen; and Y2 is -CH3, -CO2H or -CH2OH.
wherein:
A1 is H or a group having the formula Z-C(O)NHCH(C6H5)CH(OR)-C(O)-, A2 is H or CH3C(O)- and A3 is H or OH;
Z is C6H5-, C6H5CH2-O-, C(CH3)3-O- or CH(CH3)=C(CH3)-;
each of R and R1 is H or a group having the formula Y1Y2, provided that at least one of R and R1 is not H and provided that when A1 is H, R1 is not H;
Y1 is -C(O)CHX1(CH2)n1(CH=CH)n2(CH2)n3(CH=CH)n4(CH2)n5 (CH=CH)n6(CH2)n7(CH=CH)n8(CH2)n9-;
the sum of n1 + 2n2 + n3 + 2n4 + n5 +2n6 +n7 +2n8 + n9 is an integer of from 1 to 21, each of n2, n4, n6 and n8 is independently zero or 1, n1 is zero or an integer of from 1 to 21, n3 is zero or an integer of from 1 to 18, n5 is zero or an integer of from 1 to 15, n7 is zero or an integer of from 1 to 12, n9 is zero or an integer of from 1 to 9 and each of n1 to n9 can be the same or different at each occurrence;
X1 is an hydrolysis-promoting group which exhibits an electronegativity greater than hydrogen; and Y2 is -CH3, -CO2H or -CH2OH.
2. The taxane of claim 1, wherein A1 is a group having the formula Z-C(O)NHCH(C6H5)CH(OR)C(O)-.
3. The taxane of claim 2, wherein R1 is H.
4. The taxane of claim 3, wherein R is a group having the formula Y1CH3.
5. The taxane of claim 4, wherein R is -C(O)CHX1(CH2)3CH3, -C(O)CHX1(CH2)5CH3, -C(O)CHX1(CH2)9CH3, -C(O)CHX1(CH2)11CH3, or -C(O)CHX1(CH2)13CH3.
6. The taxane of claim 2, wherein R is H.
7. The taxane of claim 6, wherein R1 is a group having the formula Y1CH3.
8. The taxane of claim 7, wherein R1 is -C(O)CHX1(CH2)3CH3, -C(O)CHX1(CH2)5CH3, -C(O)CHX1(CH2)9CH3, or -C(O)CHX1(CH2)13CH3.
9. The taxane of claim 1, wherein X1 is F, Cl, Br, I, the group -OC6H4X2 or the group -C(O)X2 and wherein X2 is F, Cl, Br, I, CN, NO2 or NH3+.
10. The taxane of claim 2, wherein Z is C6H5.
11. The taxane of claim 10, wherein A2 is CH3C(O)- and wherein A3 is H.
12. The taxane of claim 11, wherein R1 is H and R is -C(O)CHX1(CH2)3CH3, -C(O)CHX1(CH2)5CH3, -C(O)CHX1(CH2)9CH3, -C(O)CHX1(CH2)11CH3, or -C(O)CHX1(CH2)13CH3.
13. The taxane of claim 12, wherein X1 is F, Cl, Br or I.
14. The taxane of claim 11, wherein R1 is H and R is -C(O)CHX1(CH2)3CH3, -C(O)CHX1(CH2)5CH3, -C(O)CHX1(CH2)9CH3, -C(O)CHX1(CH2)11CH3, or -C(O)CHX1(CH2)13CH3.
15. The taxane of claim 14, wherein X1 is F, Cl, Br or I.
16. A composition comprising the taxane of claim 1 and a pharmaceutically acceptable medium.
17. The composition of claim 16, wherein the pharmaceutically acceptable medium comprises a lipid carrier and wherein the taxane is associated with the lipid carrier.
18. The composition of claim 17, wherein the lipid carrier is a fatty acid, phospholipid, lipoprotein, micelle, lipid complex or liposome.
19. The use of anticancer effective amount of a composition according to claim for treating cancer in an animal in need thereof.
20. The use of claim 19, wherein the anticancer amount of the taxane is from 0.1 mg per kg of body weight of the animal to 1000 mg per kg.
21. The use of claim 19, wherein the taxane is associated with a liposome.
22. The use of claim 19, wherein A1 is a group having the formula C6H5C(O)NHCH(C6H5)CH(OR)C(O)-, A2 is CH3C(O)-, A3 is H and one of R or R1 is -C(O)CHX1(CH2)3CH3, -C(O)CHX1(CH2)5CH3, -C(O)CHX1(CH2)9CH3, -C(O)CHX1(CH2)9CH3, -C(O)CHX1(CH2)11CH3 or -C(O)CHX1(CH2)13CH3.
23. The use of claim 19, wherein the cancer is a lung, colon, brain, stomach, breast, ovarian cancer, prostate or stomach cancer, or a leukemia, lymphoma, sarcoma or carcinoma.
24. The use of claim 19, in combination with the use of an additional bioactive agent.
25. Use of an anticancer effective amount of a composition according to claim 16 for the manufacture of a medicament for the treatment of cancer.
26. Use according to claim 25, wherein the anticancer effective amount of the taxane is from 0.1 mg per kg of body weight of the animal to 1000 mg per kg.
27. Use according to claim 25, wherein the taxane is associated with a liposome.
28. Use according to claim 25, whereat this composition contains a taxane wherein A1 is a group having the formula C6H5C(O)NHCH(C6H5)CH(OR)C(O)-, A2 is CH3C(O)-, A3 is H and one of R or R1 is -C(O)CHX1(CH2)3CH3, -C(O)CHX1(CH2)5CH3, -C(O)CHX1(CH2)9CH3, -C(O)CHX1(CH2)11CH3 or -C(O)CHX1(CH2)13CH3.
29. Use according to claim 25, wherein the cancer is a lung, colon, brain, stomach, breast, ovarian cancer, prostate or stomach cancer, or a leukemia, lymphoma, sarcoma or carcinoma.
30. Use according to claim 25, in combination with the use of an additional bioactive agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US357595P | 1995-09-12 | 1995-09-12 | |
US60/003,575 | 1995-09-12 | ||
PCT/US1996/014631 WO1997010234A1 (en) | 1995-09-12 | 1996-09-12 | Hydrolysis-promoting taxane hydrophobic derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2231750A1 CA2231750A1 (en) | 1997-03-20 |
CA2231750C true CA2231750C (en) | 2006-07-11 |
Family
ID=21706522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002231750A Expired - Fee Related CA2231750C (en) | 1995-09-12 | 1996-09-12 | Hydrolysis-promoting taxane hydrophobic derivatives |
Country Status (22)
Country | Link |
---|---|
US (1) | US5703117A (en) |
EP (1) | EP0902783B1 (en) |
JP (1) | JP4192208B2 (en) |
KR (1) | KR100401220B1 (en) |
CN (1) | CN1100770C (en) |
AT (2) | ATE216377T1 (en) |
CA (1) | CA2231750C (en) |
CZ (1) | CZ288562B6 (en) |
DE (2) | DE69635428T2 (en) |
DK (2) | DK0902783T3 (en) |
ES (2) | ES2252347T3 (en) |
HK (1) | HK1016169A1 (en) |
HU (1) | HU226325B1 (en) |
IL (1) | IL123595A (en) |
MX (1) | MX9801871A (en) |
NO (1) | NO319521B1 (en) |
NZ (1) | NZ318300A (en) |
PL (1) | PL187738B1 (en) |
PT (1) | PT902783E (en) |
SK (1) | SK283199B6 (en) |
TR (1) | TR199800443T1 (en) |
WO (1) | WO1997010234A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107332A (en) * | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US6667053B1 (en) * | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
US5912264A (en) * | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
ES2399480T3 (en) | 1997-11-10 | 2013-04-01 | Memorial Sloan-Kettering Cancer Center | Production process of arsenic trioxide formulations |
EP1079812A4 (en) * | 1998-05-20 | 2001-12-12 | Liposome Co Inc | Novel particulate formulations |
US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
DE60004630T2 (en) * | 1999-01-12 | 2004-06-17 | Quanam Medical Corp., Santa Clara | MEDICINAL PRODUCT AND METHOD FOR ADMINISTRATING WATER-INSOLUBLE PACLITAXEL DERIVATIVES |
JP4776843B2 (en) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | Cancer composition and method using immunoconjugate and chemotherapeutic agent |
AU7007001A (en) | 2000-06-22 | 2002-01-02 | Nitromed Inc | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US6607689B1 (en) * | 2000-08-29 | 2003-08-19 | Micron Technology, Inc. | Layer thickness control for stereolithography utilizing variable liquid elevation and laser focal length |
EP1304103B1 (en) * | 2001-10-22 | 2008-12-31 | Viroblock SA | New non-phospholipid lipid vesicles (npLV) and their use in cosmetic, therapeutic and prophylactic applications |
CA2466851C (en) * | 2001-11-26 | 2012-09-11 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
EP1553924B1 (en) * | 2002-06-26 | 2010-12-08 | MediGene AG | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
JP4711947B2 (en) | 2003-02-03 | 2011-06-29 | ネオファーム、インコーポレイティッド | Taxanes and other antitumor agents encapsulated in stable filter-sterilized liposomes |
JP5139814B2 (en) * | 2005-02-18 | 2013-02-06 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Drug with improved hydrophobicity bound to a medical device |
CA2603987A1 (en) | 2005-04-12 | 2006-10-19 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
WO2009126175A1 (en) * | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
KR101721281B1 (en) | 2009-09-25 | 2017-04-10 | 위스콘신 얼럼나이 리서어치 화운데이션 | Micelle encapsulation of therapeutical agents |
CN105503844A (en) * | 2015-12-11 | 2016-04-20 | 上海大学 | C-13 and C-7 site structure modified paclitaxel compound and preparing method thereof |
CN111004195B (en) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | Cabazitaxel alkalescent derivative and preparation thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278324A (en) * | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
US5059699A (en) * | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
NZ261070A (en) * | 1992-12-23 | 1997-10-24 | Bristol Myers Squibb Co | Oxazoline-substituted taxane derivatives and their preparation; intermediates |
IL108316A (en) * | 1993-01-15 | 2006-10-31 | Univ Florida State | C10 taxane derivatives and pharmaceutical compositions containing them |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
-
1996
- 1996-09-12 ES ES02008590T patent/ES2252347T3/en not_active Expired - Lifetime
- 1996-09-12 PL PL96325477A patent/PL187738B1/en not_active IP Right Cessation
- 1996-09-12 IL IL12359596A patent/IL123595A/en not_active IP Right Cessation
- 1996-09-12 DE DE69635428T patent/DE69635428T2/en not_active Expired - Fee Related
- 1996-09-12 PT PT96930847T patent/PT902783E/en unknown
- 1996-09-12 DE DE69620802T patent/DE69620802T2/en not_active Expired - Fee Related
- 1996-09-12 CA CA002231750A patent/CA2231750C/en not_active Expired - Fee Related
- 1996-09-12 DK DK96930847T patent/DK0902783T3/en active
- 1996-09-12 TR TR1998/00443T patent/TR199800443T1/en unknown
- 1996-09-12 CZ CZ1998711A patent/CZ288562B6/en not_active IP Right Cessation
- 1996-09-12 NZ NZ318300A patent/NZ318300A/en unknown
- 1996-09-12 EP EP96930847A patent/EP0902783B1/en not_active Expired - Lifetime
- 1996-09-12 KR KR10-1998-0701653A patent/KR100401220B1/en not_active IP Right Cessation
- 1996-09-12 WO PCT/US1996/014631 patent/WO1997010234A1/en active IP Right Grant
- 1996-09-12 DK DK02008590T patent/DK1229030T3/en active
- 1996-09-12 CN CN96198237A patent/CN1100770C/en not_active Expired - Fee Related
- 1996-09-12 US US08/712,684 patent/US5703117A/en not_active Expired - Fee Related
- 1996-09-12 MX MX9801871A patent/MX9801871A/en not_active IP Right Cessation
- 1996-09-12 AT AT96930847T patent/ATE216377T1/en not_active IP Right Cessation
- 1996-09-12 HU HU9901433A patent/HU226325B1/en unknown
- 1996-09-12 ES ES96930847T patent/ES2179208T3/en not_active Expired - Lifetime
- 1996-09-12 AT AT02008590T patent/ATE309235T1/en not_active IP Right Cessation
- 1996-09-12 SK SK334-98A patent/SK283199B6/en unknown
- 1996-09-12 JP JP51210297A patent/JP4192208B2/en not_active Expired - Fee Related
-
1998
- 1998-03-11 NO NO19981071A patent/NO319521B1/en unknown
-
1999
- 1999-03-18 HK HK99101119A patent/HK1016169A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2231750C (en) | Hydrolysis-promoting taxane hydrophobic derivatives | |
KR100386002B1 (en) | Hydrophobic taxane derivatives | |
US6482850B2 (en) | Hydrolysis-promoting hydrophobic taxane derivatives | |
JP6437968B2 (en) | Modified drugs for use in liposomal nanoparticles | |
US6051600A (en) | Liposomal hydrolysis-promoting hydrophobic taxane derivatives | |
EP1229030B1 (en) | Hydrolysis-promoting taxane hydrophobic derivates | |
AU706290C (en) | Hydrolysis-promoting taxane hydrophobic derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20090914 |